Olatec Therapeutics

Olatec is a Phase 2 clinical stage biotech company at the forefront of an emerging class of innovative, oral inflammation therapeutics. The Company’s lead drug candidate, dapansutrile, is a proprietary specific NLRP3 inhibitor. The Company has advanced dapansutrile from discovery to its current later-stage clinical development in arthritis, diabetes, neuroinflammatory diseases and cancer. Dapansutrile is positioned to become a breakthrough treatment with early human data showing its potential to safely modulate the body’s immune system allowing for the restoration of immune balance, a necessary step to treat or prevent disease progression and prognosis in patients. Olatec’s preclinical and clinical studies have been published in top medical and scientific journals. On the strength of dapansutrile’s benign safety profile and robust clinical data, Olatec’s clinical trials are now being conducted in well-known international centers of excellence. With a mission to translate scientific potential into medical practice and become best-in-class in treating chronic inflammation that drives disease progression with a cost-effective and patient-friendly (orally dosed) therapeutic. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands.